Macimorelin

Cat. No.: HY-14820

CAS No.: 381231-18-1

Molecular Formula: $C_{26}H_{30}N_6O_3$

Molecular Weight: 474.55

Target: GHSR

Pathway: GPCR/G Protein

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Macimorelin (EP-1572), a GH secretagogue, is an orally active GHSR agonist. Macimorelin stimulates GH release. Macimorelin can be used in the research of adult growth hormone deficiency (AGHD), and Cancer anorexia-cachexia syndrome (CACS)[1][2][3].
IC_{50} & Target	GHSR[1]
In Vivo	Macimorelin (5 mg/kg, i.p. twice daily for 2 weeks) decreases the number and duration of seizures in IHKA mouse model[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Intrahippocampal kainic acid (IHKA) mouse model[2]
Dosage:	5 mg/kg
Administration:	Intraperitoneal injection (i.p.), twice daily for 2 weeks.
Result:	Significantly decreased the number and duration of seizures during the treatment period, but had no antiepileptogenic or disease-modifying effect.

REFERENCES

[1]. Jose M Garcia, et al. Macimorelin as a Diagnostic Test for Adult GH Deficiency. J Clin Endocrinol Metab. 2018 Aug 1;103(8):3083-3093.

[2]. An Buckinx, et al. Translational potential of the ghrelin receptor agonist macimorelin for seizure suppression in pharmacoresistant epilepsy. Eur J Neurol. 2021 Sep;28(9):3100-3112.

[3]. Ali SA, Garcia JM. Randomized clinical trial of the novel oral ghrelin mimetic macimorelin in the treatment of cancer cachexia: study design and preliminary results. Endocr Rev. 2013;34:

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA